Last updated: June 23, 2026

OSMOVIST 190 market dynamics and financial trajectory

Executive summary: OSMOVIST 190 (iopamidol 190 mg I/mL) is a low-to-mid single-injection radiology contrast product with pricing and volume driven by imaging utilization, hospital group tendering, competitive supply of iodinated contrast media, and periodic regulatory or supply disruptions. Financial trajectory is dominated by (1) reimbursement pressure and tender-based ASP compression in major EU markets, (2) shift in use patterns toward CT and standardized contrast protocols, and (3) loss-of-exclusivity effects and generic or biosimilar-like competition from other non-ionic iodinated monomer and dimer contrast agents where labeling or concentration parity exists.

What is OSMOVIST 190 and where is it sold?

Answer: OSMOVIST 190 is an iodinated, non-ionic contrast medium used for intravascular or cavity imaging, formulated at 190 mg iodine per mL. It competes in the broader iodinated contrast media category against other iopamidol strengths and other iodine concentrations from non-ionic agents (typically 240–370 mg I/mL) depending on imaging modality and protocol.

Indication and use pattern drivers

CT share growth typically increases absolute contrast consumption, but per-scan utilization depends on patient size, imaging protocol, and dose optimization.
Radiology departments standardize contrast selection through:
- formulary and purchasing contracts
- protocol pathways (e.g., contrast volume, injection rate)
- supply reliability and incident history

Typical demand base

Hospital and outpatient imaging centers are the core buyers.
Demand is “accessed” through contracts, tenders, and pharmacy distribution agreements more than through branded physician preference.

Market dynamic implication: OSMOVIST 190’s revenue path tracks imaging throughput and procurement friction. Where 190 mg I/mL is preferred for specific workflows, volume can be resilient even when category pricing declines.

How do tender pricing, reimbursement, and ASP work for OSMOVIST 190?

Answer: ASPs for iodinated contrast media are highly tender-driven. Even without direct price transparency, category experience shows that:

hospital group procurement pushes annual pricing down or forces rebates
switching costs are limited if clinically equivalent and supply can be assured
reimbursement tightens pressure on ASP in markets with reference pricing and prescribing restrictions

Key financial mechanism: hospital contract re-pricing cycles

Most European and many public-sector systems re-price products during tender cycles (often annual or biennial).
Contrast media can see discrete ASP drops at contract renewal rather than smooth erosion.

Demand elasticity is low, price elasticity is not

Imaging volumes are driven by clinical throughput and capacity.
Consumption per scan can shift with protocols, but the category generally sustains demand even when price declines.

Market dynamic implication: OSMOVIST 190 financial performance is likely to show step-down patterns in revenue growth when contracts reset ASP, followed by stabilization if volumes hold.

What patent estate and exclusivity position affects OSMOVIST 190 revenue?

Answer: OSMOVIST 190 is an older small-molecule contrast agent formulation and concentration. Revenue trajectory in such products is usually shaped less by ongoing exclusivity and more by market share vs. supply competition among multiple equivalent products (often with similar active ingredient and strength).

How “market exclusivity” typically works in contrast media

Even when patent protection exists on certain formulations, the category often has multiple authorized equivalents.
Economic exclusivity is driven by:
- packaging and logistics
- contract incumbency
- supply chain credibility
- ability to meet procurement specifications faster than competitors

Commercial consequence

Branded-like revenue durability is usually limited once generics or equivalent equivalents are widely available.
Market share shifts more quickly than in specialty therapeutic areas because interchangeability is common.

Market dynamic implication: OSMOVIST 190’s financial trajectory should be expected to reflect category competition rather than sustained brand-premium pricing.

When does OSMOVIST 190 lose exclusivity or face equivalent competition pressure?

Answer: The strongest “loss-of-exclusivity” pressure for iodinated contrast products typically occurs when equivalent versions with the same active ingredient and comparable strength become widely tender-eligible and competitively priced. For older agents like iopamidol 190, this pressure has historically appeared after broader market authorization of equivalents and consolidation of procurement frameworks.

Pressure points that cause revenue step-downs

Tender qualification criteria change (e.g., pack size, supply SLAs, compliance)
Competitive bids undercut ASP during renewal
Stock availability constraints create temporary volume swings, followed by normalization

Market dynamic implication: Expect volatility around procurement events and supply disruptions rather than a single predictable “one date” exclusivity cliff, because market substitution happens through contract awards.

Which companies compete with OSMOVIST 190 in iodinated contrast media?

Answer: OSMOVIST 190 competes within the iodinated contrast media landscape against:

other iopamidol-labeled products (often different pack sizes or concentrations)
alternative non-ionic iodinated contrast agents (e.g., iopromide, iohexol, ioversol, iomeprol) where protocol allow substitution

Competitive dynamics that matter financially

Supply reliability: tenders often award to suppliers with low disruption risk.
Dosing protocols: some modalities use fixed concentration bands and can switch among agents if iodine delivery and viscosity requirements are compatible.
Pack and handling: prefilled units vs. vials affect usability and procurement preferences.

Market dynamic implication: Even if clinical equivalence is accepted, contract winning depends on logistics and bid economics. OSMOVIST 190’s trajectory is therefore linked to its distributor and manufacturing continuity.

How does OSMOVIST 190 compare with higher iodine concentration alternatives (e.g., 240–370 mg I/mL)?

Answer: Concentration choice is driven by required iodine delivery, injection rate feasibility, and imaging protocol. OSMOVIST 190 can lose share when sites standardize on higher concentration agents that reduce volume per scan, provided viscosity and protocol constraints are manageable.

Where 190 mg I/mL can hold share

protocols requiring lower iodine concentration
pediatric or dose-optimized workflows if clinical guidelines prefer 190 mg I/mL
sites with existing contract alignment and protocol stability

Where 190 mg I/mL can lose share

standardized CT protocols that prefer higher concentration for reduced injection volume
tender awards that favor a supplier’s portfolio bundle across multiple concentrations

Market dynamic implication: Share shifts can occur without changes to imaging demand, purely due to concentration standardization.

What FDA and regulatory status affects OSMOVIST 190 availability and commercialization?

Answer: OSMOVIST 190 is regulated as a contrast medium in its marketed jurisdictions. Regulatory status affects commercial continuity through:

market authorization and labeling approvals
manufacturing site inspections and batch release timelines
safety communications that can trigger usage pauses

Regulatory events that influence revenue

supply interruptions caused by manufacturing or quality issues
label updates changing contraindications or dose guidance
distribution restrictions after adverse event signals

Market dynamic implication: Revenue trajectories for iodinated contrast products can show temporary dips during regulatory-driven disruptions, followed by recovery if supply returns quickly.

What Orange Book status exists for OSMOVIST 190 and what does it imply?

Answer: OSMOVIST 190, as an iodinated small-molecule contrast medium, is generally not where value is anchored by long-lived Orange Book-style exclusivity in the same way as oncology or rare disease drugs. The commercial logic usually follows authorization status and contract eligibility more than patent enforcement.

Market implication

When multiple approved equivalents exist, patent-based barriers are often weaker than procurement-based barriers.
Litigation and Paragraph IV dynamics are typically less central for category competition than in brand-to-generic oral drugs.

Market dynamic implication: Financial trajectory is more sensitive to contract awards and supply than to legal exclusivity timelines.

How does OSMOVIST 190 revenue typically behave during generic entry or equivalent substitution?

Answer: For contrast media, equivalent substitution often drives:

ASP declines tied to competitive bids
volume stability if the product remains formulary-approved
share losses if protocol standardization or tender awards favor competitors

Revenue decomposition framework

Revenue = volume × ASP
Volume is impacted by contract share and protocol preferences.
ASP is impacted by tender pricing and rebate structures.

Market dynamic implication: Even if volumes hold, revenue can fall due to ASP compression at renewal.

What patent litigation or settlement risk exists for OSMOVIST 190?

Answer: Litigation is usually less dispositive for contrast media market dynamics than it is for branded small molecules with strong exclusivity and clear regulatory carve-outs. The dominant economic driver is the ability of competitors to bid into tenders with authorized, supply-capable products.

Practical litigation effects if they occur

temporary sales interruptions through injunctions
delayed tender qualification or launch timing
switching back to incumbent supplies after settlements

Market dynamic implication: Unless a rare injunction affects supply, the category typically moves quickly through procurement rather than through litigation-led barriers.

What are the main supply chain and manufacturing risks impacting OSMOVIST 190 financial trajectory?

Answer: Contrast media economics can swing with:

manufacturing constraints and batch release lead times
raw material availability and production capacity
distribution bottlenecks affecting hospital stocking

Supply shocks translate directly into revenue volatility

hospitals can substitute approved alternatives if a product is unavailable
when supply returns, restoring share can take time because tender contracts and protocol checklists may have shifted

Market dynamic implication: Expect “spike then step-down” patterns around supply disruptions: revenue loss during shortages can create longer recovery periods than in products with easier pharmacy re-stocking.

What does the financial trajectory look like across a typical 3- to 5-year horizon for contrast media like OSMOVIST 190?

Answer: While specific company financials require exact reporting, the category pattern is consistent:

Initial years: volume growth driven by adoption, contract entry, and imaging demand
Mid phase: ASP compression during tender renewals
Later phase: share consolidation among low-cost, reliable supply products, with revenue growth flattening or declining in nominal terms unless pricing stabilizes

Observable metrics that track trajectory

hospital contract awards (winners gain incremental volume)
ASP or list price changes around tenders
distribution continuity and in-stock rates
concentration standardization (191–200 mg I/mL vs. 240–370 mg I/mL)

Market dynamic implication: For products like OSMOVIST 190, financial trajectory is likely to be flat to declining in nominal terms unless the product gains share in new contracts or pricing rebounds after tender overshoot.

Key Takeaways

OSMOVIST 190 is driven by iodinated contrast media category economics: hospital tender pricing, imaging volumes, and protocol-driven concentration preferences.
Financial trajectory is typically characterized by ASP compression at contract renewal, with volume gains or losses determined more by contracting and supply reliability than by therapeutic differentiation.
Competitive pressure comes from authorized equivalents and alternative non-ionic iodinated agents, with substitution enabled by clinical interchangeability and tender eligibility.
Expected volatility is most pronounced around supply disruptions, regulatory-driven batch release delays, or shifts in concentration standardization.

FAQs

How does contrast media tendering differ between public hospitals and private imaging centers for products like OSMOVIST 190?
What protocol factors determine whether a site prefers 190 mg I/mL instead of 240–370 mg I/mL for CT?
How do packaging formats (vial vs prefilled) and pack size influence contracting outcomes for iodinated contrast media?
What supply reliability metrics predict whether a hospital will switch away from an incumbent contrast supplier?
How does reference pricing or formulary restriction change ASP trajectory for non-ionic iodinated contrast media in EU markets?

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA).
FDA. Drug Safety Information and Adverse Event Reporting for contrast media. (FDA).
EMA. European Medicines Agency product information and variations for iodinated contrast media. (EMA).

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	26
Patent Applications:	1,302
DailyMed Link:	OSMOVIST 190 at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	OSMOVIST 190	iotrolan	INJECTABLE;INTRATHECAL	019580-001	Dec 7, 1989		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

OSMOVIST 190 Drug Patent Profile

Which patents cover Osmovist 190, and when can generic versions of Osmovist 190 launch?

AI Deep Research

Questions you can ask:

Summary for OSMOVIST 190

US Patents and Regulatory Information for OSMOVIST 190